Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Radiation Injuries 1Prostatic Neoplasms 1Non-alcoholic Fatty Liver Disease 1Carcinoma, Hepatocellular 1

Interventions

Radiotherapy 6Chemoradiotherapy 2sodium propionate 1olaparib 1Xylitol 1Surgical Procedures, Operative 1Re-Irradiation 1Radiography, Panoramic 1Poly A 1Oral Hygiene 1Menogaril 1Lymph Node Excision 1Lisinopril 1Immunotherapy 1Heavy Ion Radiotherapy 1Fatty Acids, Volatile 1Dexamethasone 1Consolidation Chemotherapy 1Butyric Acid 1Blood Specimen Collection 1Bevacizumab 1Betaine 1Androgen Antagonists 1Adrenal Cortex Hormones 1Adenosine Diphosphate Ribose 1Adenosine Diphosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Radiation Injuries × Lisinopril × 1 year × Clear all
NCT05530655 2026-01-13

A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

University of Rochester

Phase EARLY_PHASE1 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms, Radiation Injuries

Data powered by HemOnc (CC BY 4.0) Colophon âš¡